Possible usefulness of apocynin, an NADPH oxidase inhibitor, for nitrate tolerance: Prevention of NO donor-induced endothelial cell abnormalities

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 1, 2007, Pages

  Fukatsu, Akiko ^a   Hayashi, Toshio ^a   Miyazaki Akita, Asaka ^a   Matsui Hirai, Hisako ^a   Furutate, Yukie ^a   Ishitsuka, Asako ^a   Hattori, Yuichi ^b   Iguchi, Akihisa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Bovine aortic endothelial cells; Endothelial nitric oxide synthase; Nitrate free interval; Nitroglycerin; Reactive oxygen species

Indexed keywords

APOCYNIN; ARGININE METHYL ESTER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; NITRATE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; AORTA; ARTICLE; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ACETOPHENONES; ANIMALS; CATTLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG TOLERANCE; ENDOTHELIAL CELLS; ENZYME INHIBITORS; NADPH OXIDASE; NITRATES; NITRIC OXIDE DONORS; REACTIVE OXYGEN SPECIES;

EID: 34547110532     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01141.2006     Document Type: Article

References (41)

1. Abrams J. Interval therapy to avoid nitrate tolerance: paradise regained? Am J Cardiol 64: 931-934, 1989.
2. Cathcart R, Schwiers E, Ames BN. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Biochem 134: 111-116, 1983.
3. Chen JX, Berry LC, Tanner M, Chang M, Myers RP, Meyrick B. Nitric oxide donors regulate nitric oxide synthase in bovine pulmonary artery endothelium. J Cell Physiol 186: 116-123, 2001.
4. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 99: 8306-8311, 2002.
5. Cowan JC, Bourke JP, Reid DS, Julian DG. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 60: 271-275, 1987.
6. Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, Schildknecht S, Bachschmid M, Nazirisadeh Y, Ullrich V, Mülsch A, Münzel T, Tsilimingas N. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 338: 1865-1874, 2005.
7. Daiber A, Mülsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, Münzel T. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol 96: 25i-36i, 2005.
8. - through endothelial GTPCH1 and NADPH oxidase. Life Sci 75: 3185-3194, 2004.
9. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohormonal activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 16: 923-931, 1990.
10. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 358: 113-122, 1998.
11. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur Heart J 10: 998-1002, 1989.
12. Freedman SB, Daxini BV, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol 25: 349-355, 1995.
13. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 106: 2404-2408, 2002.
14. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234, 1995.
15. Gruhn N, Aldershvile J, Boesgaaed S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol 416: 245-249, 2001.
16. Jayachandran M, Hayashi T, Sumi D, Iguchi A, Miller VM. Temporal effects of 17β-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327-H1333, 2001.
17. Kooy NW, Royall JA. Agonist-induced peroxynitrite production from endothelial cells. Arch Biochem Biophys 310: 352-359, 1994.
18. Kurz S, Hink U, Nickenig G, Borthayre AB, Harrison DG, Münzel T. Evidence for causal role of the renin-angiotensin system in nitrate tolerance. Circulation 99: 3181-3187, 1999.
19. Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb 32: 359-360, 2002.
20. McVeigh GE, Hamilton P, Wilson M, Hanratty CG, Leahey WJ, Devine AB, Morgan DG, Dixon LJ, McGrath LT. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation 106: 208-213, 2002.
21. Matsubara T, Ziff M. Superoxide anion release by human endothelial cells: synergism between a phorbol ester and a calcium ionophore. J Cell Physiol 127: 207-210, 1986.
22. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25: 274-278, 2005.
23. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618-628, 2005.
24. Münzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting action of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98: 1465-1470, 1996.
25. Münzel T, Hink U, Yigit H, Macharzina R, Harrison DG, Mülsch A. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol 127: 1224-1230, 1999.
26. Münzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, Oelze M, Skatchkov M, Warnholtz A, Duncker L, Meinertz T, Förstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOSIII) gene expression, NOSIII-mediated superoxide production, and vascular NO bioavailability. Circ Res 86: E7-E12, 2000.
27. Münzel T, Mollnau H, Hartmann M, Geiger C, Oelze M, Warnholtz A, Yehia AH, Förstermann U, Meinertz T. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 36: 628-634, 2000.
28. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618-628, 2005.
29. Otto A, Fontaine J, Tschirhart E, Fontaine D, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br J Pharmacol 148: 544-552, 2006.
30. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 91: 973-978, 1995.
31. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 338: 520-531, 1998.
32. Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 39: 1199-1203, 2002.
33. Pearse DB, Dodd JM. Ischemia-reperfusion lung injury is prevented by apocynin, a novel inhibitor of NADPH oxidase. Chest 116: 55S-56S, 1999.
34. Pepine CJ, Lopez LM, Bell DM, Handberg-Thurmond EM, Marles RG, McGorray S. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the Second Transdermal Intermittent Dosing Evaluation Study (TIDES-II). J Am Coll Cardiol 30: 955-961, 1997.
35. Ratz JD, McGuire JJ, Anderson DJ, Bennett BM. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther 293: 569-577, 2000.
36. Schulz E, Anter E, Keaney JF Jr. Oxidative stress, antioxidants, and endothelial function. Curr Med Chem 11: 1093-1104, 2004.
37. Sheehy AM, Burson MA, Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol Lung Cell Mol Physiol 274: L833-L841, 1998.
38. phox mRNA and protein expression in THP-1 cells. Biochim Biophys Acta 1640: 113-118, 2003.
39. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mülsch A, Schulz E, Keaney JF Jr, Stamler JS, Münzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113: 482-489, 2004.
40. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol Heart Circ Physiol 262: H1915-H1919, 1992.
41. Valentine JS, Miksztal AR, Sawyer DT. Methods for the study of superoxide chemistry in nonaqueous solutions. Methods Enzymol 105: 71-81, 1984.